Medicare can pay for obesity drugs like Wegovy in certain heart patients
Time:2024-05-21 06:24:06 Source:politicsViews(143)
Medicare can pay for the popular weight-loss drug Wegovy — as long as the patients using it also have heart disease and need to reduce the risk of future heart attacks, strokes and other serious problems, federal officials said Thursday.
The Centers for Medicare & Medicaid Services issued new guidance that says Medicare Part D drug benefit plans — which are offered through private insurers — could cover anti-obesity drugs that are approved for an additional use.
The move could pave the way for thousands of new prescriptions, resulting in billions of dollars in increased spending, analysts have said.
In practice, the guidance opens the door to wider coverage of Wegovy, the brand name of Novo Nordisk’s obesity medication semaglutide. The U.S. Food and Drug Administration this month approved a label change that allows Wegovy to be used to reduce the risk of cardiovascular events in people who are overweight or have obesity and also have existing heart disease.
Previous:California congressman urges closer consultation with tribes on offshore wind
Next:Socialite Jasmine Hartin enjoys beach snuggle with electrician hunk
You may also like
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed
- Labour's flip
- 'Killer' father is seen 'crying' without shedding tears as court hears how he tortured six
- Thousands of pro
- Saudi Arabia is going to sponsor the WTA women's tennis rankings under a new partnership
- Thousands of pro
- Sanchez grabs biggest career win on Giro Stage 6 and Pogacar stays in front
- I'm a vet and you should beware of these 4 garden plants that are harmful to dogs
- The unstoppable duo of Emma Stone and Yorgos Lanthimos